Maze Therapeutics

harnessing the power of genetics to transform the lives of patients

In the summer of 2018, we had an idea. A big idea, inspired by the recent dramatic advances in the field of genetics and the significant gaps in translating those into medicines. We set out to use these advances in harnessing the power of genetics to transform the lives of patients, which became our company’s mission.

While we have a passion for advanced science and pride ourselves on excellence in execution, ultimately, everything we do is for patients—to both extend the lives of patients with serious disease and transform the quality of their lives. Taking on this challenge requires a top team with the right resources, capabilities, and a commitment to a delivering on this commitment to patients with important new medicines.

Our Core Values

We strive to make every day at work count, and as scientists and members of the biotech community, we believe it is our obligation to decode the genetic mysteries that drive the diseases of the patients we aim to serve.

We live each day by our Maze values:

Further Together.

Impact Obsessed.

Stand True.

Maze Leadership Team

Board of Directors

Charles Homcy, M.D.

Chairman of the Board; Partner, Third Rock Ventures

Dr. Charles Homcy is a partner at Third Rock Ventures, where he focuses on the formation of companies that discover and develop novel therapeutic approaches. He brings significant experience building and leading successful biotech companies and has played an integral…

View full bio

Nancy Andrews, M.D., Ph.D

DEAN EMERITA, DUKE UNIVERSITY SCHOOL OF MEDICINE

Nancy Andrews, M.D., Ph.D., has extensive experience as a physician, scientist, professor and senior administrator at leading academic institutions and hospitals. Her distinguished career spans more than 30 years, with leadership roles at both Harvard Medical School and the Duke…

View full bio

Brendan Bulik-Sullivan, Ph.D.

Partner, GV

Dr. Brendan Bulik-Sullivan is a partner at GV focusing on life sciences investments. Before GV, Dr. Bulik-Sullivan worked on applied statistics and machine learning research in genetics and biotechnology. Dr. Bulik-Sullivan led machine learning at Gritstone Oncology, where he designed…

View full bio

Jason Coloma, Ph.D.

Chief Executive Officer

Dr. Jason Coloma is the Chief Executive Officer of Maze Therapeutics. Prior to his appointment to CEO, he was Maze’s chief operating officer and a venture partner at Third Rock Ventures, where he was instrumental in the founding and launch…

View full bio

Sekar Kathiresan, M.D.

Verve Therapeutics, MGH and Broad

Dr. Sek Kathiresan, a physician scientist and a human geneticist, is the CEO of Verve Therapeutics, Professor of Medicine (on leave) at Harvard Medical School, and Institute Member (on leave) at Broad Institute. Sek leverages human genetics to understand the…

View full bio

Jonathan Lim, M.D.

Founder and managing partner, City Hill Ventures

Jonathan Lim, M.D., is the founder and managing partner at City Hill Ventures. In addition to his role at City Hill, Dr. Lim is a venture partner at ARCH Venture Partners, chairman, chief executive officer and co-founder at Erasca, and…

View full bio

Richard Scheller, Ph.D.

Former head of therapeutics and chief scientific officer, 23andMe

Dr. Richard Scheller is the former head of therapeutics and chief scientific officer of 23andMe. Prior to his role there, he spent 14 years at Genentech where he was executive vice president of research and early development. He served on…

View full bio

Catherine Angell Sohn, Pharm.D.

FORMER Senior Vice President GLAXOSMITHKLINE; ADJUNCT PROFESSOR AT UCSF

Catherine Angell Sohn, Pharm.D., is an experienced biopharmaceutical executive and board member with expertise in strategy, strategic product development, business development, commercialization of new medicines and corporate governance. Dr. Sohn currently serves as an independent director on the Boards of…

View full bio

Daniel K. Spiegelman

FORMER Executive Vice President, Chief Financial Officer, BIOMARIN PHARMACEUTICALS

Daniel K. Spiegelman has served as a chief financial officer in several diversified biotechnology companies spanning 30 years. He was most recently executive vice president and chief financial officer of BioMarin Pharmaceuticals, Inc., a pharmaceutical company focused on development of…

View full bio

Andy Tran

Matrix Capital Management

Andy Tran leads and oversees key private biotechnology investments at Matrix Capital Management, a technology and life sciences investment firm. In addition to serving as Board Director of Maze Therapeutics, he has led investments in and served on the boards…

View full bio

Jeffrey Tong, Ph.D.

Partner, Third Rock Ventures

Dr. Jeffrey Tong is a partner with Third Rock Ventures, where he focuses on drug discovery and development across the firm’s portfolio. He is chairman of Ambys Medicines, and also serves on the board of Nurix Therapeutics. Prior to joining…

View full bio

Founders

Mark Daly, Ph.D.

Broad Institute

Dr. Mark Daly is an institute member of the Broad Institute, co-director of the Program in Medical and Population Genetics and the director of the Institute for Molecular Medicine Finland. His research primarily focuses on the development and application of…

View full bio

Stephen Elledge, Ph.D.

Harvard Medical School and Brigham and Women’s Hospital

Dr. Stephen Elledge is a world-renowned leader in the field of the genetics, biochemistry, genomics, and proteomics of cancer cell biology. He is currently the Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School and Brigham and Women’s…

View full bio

Aaron D. Gitler, Ph.D.

Stanford University

Dr. Aaron Gitler is professor of genetics at Stanford University. One of his most pivotal discoveries was the identification of a major genetic contributor to amyotrophic lateral sclerosis (ALS). Aaron’s team recently demonstrated that inhibiting this gene markedly extends lifespan…

View full bio

Jonathan S. Weissman, Ph.D.

WHITEHEAD INSTITUTE

Dr. Jonathan S. Weissman currently serves as professor of biology and member of the Whitehead Institute. He is also an investigator at the Howard Hughes Medical Institute and co-leads the Laboratory for Genomic Research, funded by GlaxoSmithKline, which drives development…

View full bio

Sekar Kathiresan, M.D.

Verve Therapeutics, MGH and Broad

Dr. Sek Kathiresan, a physician scientist and a human geneticist, is the CEO of Verve Therapeutics, Professor of Medicine (on leave) at Harvard Medical School, and Institute Member (on leave) at Broad Institute. Sek leverages human genetics to understand the…

View full bio

Charles Homcy

M.D., CEO; Partner, Third Rock Ventures

Dr. Charles Homcy is a partner at Third Rock Ventures, where he focuses on the formation of companies that discover and develop novel therapeutic approaches. He brings significant experience building and leading successful biotech companies and has played an integral role in the launching and building of Third Rock Ventures’ portfolio companies, including Ambys Medicines, Global Blood Therapeutics, Pliant Therapeutics, Relay Therapeutics, Goldfinch Bio, CytomX and MyoKardia.